The global Respiratory Virus Infection Drugs market accrued earnings worth approximately 40.12 (USD Billion) in 2020 and is predicted to gain revenue of about 57.23(USD Billion) by 2028, is set to record a CAGR of nearly 7.5% over the period from 2021 to 2028.
The global Respiratory Virus Infection Drugs market accrued earnings worth approximately 40.12 (USD Billion) in 2020 and is predicted to gain revenue of about 57.23(USD Billion) by 2028, is set to record a CAGR of nearly 7.5% over the period from 2021 to 2028. The report offers assessment and analysis of the Respiratory Virus Infection Drugs market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2020 along with a forecast from 2021 to 2028 based on revenue (USD Billion).
Report Scope :
Report Attribute | Details |
---|---|
Base Year | 2020 |
Historic Years | 2016 - 2020 |
Forecast Years | 2021 - 2028 |
Segments Covered | By Product Type, By Application, and By End Use |
Forecast Units | Value (USD Billion), and Volume (Units) |
Quantitative Units | Revenue in USD million/billion and CAGR from 2021 to 2028 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
Number of Companies Covered | 10 companies with scope for including additional 15 companies upon request |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization Scope | Avail customized purchase options to meet your exact research needs. |
Respiratory Virus Infection Drugs Market: Overview
Respiratory viruses such as influenza, coronavirus, Para influenza, rhinovirus, respiratory syncytial virus, and human metapneumovirus are the most common causes of respiratory virus infections in immuno-compromised persons. Moreover, early diagnosis & treating of these infections through drugs can prove to be effective & beneficial for immuno-compromised patients affected due to respiratory virus infections since viral replication & invasive infection can prove to be fatal. Since past few years newly emerging viral respiratory pathogens such as avian influenza, pandemic influenza, SARS-CoV, and MERS-CoV have been constantly posing challenge to private as well as public healthcare systems. Hence, there is a growing necessity for developing cost-efficient anti-viral agents & drugs. Recently, antiviral drugs are being developed by virologists & pharmaceutical firms for targeting viral entry, virus replication, and virus release for inhibiting proliferation & blocking growth & spread of virus in human body.
According to NIH researchers, Amantadine and Rimantadine medicines/pharmacokinetics are used for inhibiting replication of influenza A virus through interfering with viral M2 protein activity. Moreover, both Amantadine and Rimantadine have proved to be effective in low proportions against influenza B virus. Reportedly, both these drugs are administered in oral form as tablets or in syrup form at 5mg per kg of body mass for children. They are administered nearly up to 200 mg per day for adults. As per clinical trials, both Amantadine and Rimantadine have proved effective in preventing influenza in over 60% of subjects. For the record Zanamivir and Oseltamivir available for oral administration in powdered, capsule, and liquid form has also helped in preventing influenza infections in over 65% of subjects.
Respiratory Virus Infection Drugs Market: Growth Drivers
Massive use of artificial intelligence and machine learning in drug discovery is projected to favorably influence growth of respiratory virus infection drugs market. Humungous use of combination therapy is projected to boost rate of success of treating respiratory virus infection through anti-viral drugs. This, in turn, will facilitate elevation of respiratory virus infection drugs market size in upcoming years. Apart from this, effective drug delivery through nanotechnology is projected to provide new growth prospects for respiratory virus infection drugs market in near future. In addition to this, rise in healthcare spending & surge in vaccination activities will spur respiratory virus infection drugs industry growth. With AI-based multi-program model enabling production of antibiotic resistance drug molecules for various kinds of harmful viruses, the market for respiratory virus infection drugs is anticipated to gain traction in the years ahead. Giant pharma firms are trying to enter into partnerships with other local or regional pharma firms for developing new drugs for treating respiratory virus infections in children, thereby helping respiratory virus infection drugs market explore new areas of growth in ensuing years. Nonetheless, easy access to generic drug substitutes can pose a threat to growth of respiratory virus infection drugs market in near future.
Regional Landscape
North American Market To Hit New Terrains of Growth By 2028
Expansion of respiratory virus infection drugs market during 2021-2028 can be attributed to new drug approvals by regulatory authorities such as U.S. FDA. Apart from this, presence of enhanced healthcare amenities along with early acceptance of advanced therapeutics in healthcare sector in countries like Canada and the U.S. will help respiratory virus infection drugs market in North America gain acceleration. Apart from this, growing healthcare awareness among the people and easy access to diagnostic tests in sub-continent will further contribute towards growth of respiratory virus infection drugs market in North America during 2021-2028.
Competitive Landscape
Key players leveraging industry landscape and profiled in report include AstraZeneca, AbbVie, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., Roche Diagnostics Limited, Orion Corporation, Cipla, Inc., Sanofi, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, and Merck & Co., Inc.
The global Respiratory Virus Infection Drugs Market is segmented as follows:
By Drug Type
By Infection Type
By Distribution Channel
By Route of Administration
By Region
List of Figures
1. Market research Type
2. Market research methodology
3. Global Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
4. Porter’s Five Forces Analysis
5. Global Respiratory Virus Infection Drugs Marketattractiveness, By Drug Type
6. Global Respiratory Virus Infection Drugs Marketattractiveness, By Route of Administration
7. Global Respiratory Virus Infection Drugs Marketattractiveness, By Infection Type
8. Global Respiratory Virus Infection Drugs Marketattractiveness, By Distribution Channel
9. Global Respiratory Virus Infection Drugs Marketshare by Drug Type ,2020 and 2028 (USD Billion)
10. Global Respiratory Virus Infection Drugs Marketby Antibiotics, 2018–2028(USD Billion)
11. Global Respiratory Virus Infection Drugs Marketby Nasal Decongestants, 2018–2028(USD Billion)
12. Global Respiratory Virus Infection Drugs Marketby Non-Steroidal Anti-Inflammatory Drugs, 2018–2028(USD Billion)
13. Global Respiratory Virus Infection Drugs Marketby Cough Suppressants, 2018–2028(USD Billion)
14. Global Respiratory Virus Infection Drugs Marketshare by Infection Type ,2020 and 2028 (USD Billion)
15. Global Respiratory Virus Infection Drugs Marketby Respiratory Syncytial Virus Infection , 2018–2028(USD Billion)
16. Global Respiratory Virus Infection Drugs Marketby Influenza Virus Infection, 2018–2028(USD Billion)
17. Global Respiratory Virus Infection Drugs Marketby Para Influenza Virus Infection, 2018–2028(USD Billion)
18. Global Respiratory Virus Infection Drugs Marketby Rhinovirus Infection, 2018–2028(USD Billion)
19. Global Respiratory Virus Infection Drugs Marketby Adenovirus Infection, 2018–2028(USD Billion)
20. Global Respiratory Virus Infection Drugs Marketshare by Route of Administration ,2020 and 2028 (USD Billion)
21. Global Respiratory Virus Infection Drugs Marketby Oral, 2018–2028(USD Billion)
22. Global Respiratory Virus Infection Drugs Marketby Parenteral, 2018–2028(USD Billion)
23. Global Respiratory Virus Infection Drugs Marketshare by Distribution Channel ,2020 and 2028 (USD Billion)
24. Global Respiratory Virus Infection Drugs Marketby Hospital Pharmacies, 2018–2028(USD Billion)
25. Global Respiratory Virus Infection Drugs Marketby Retail Pharmacies, 2018–2028(USD Billion)
26. Global Respiratory Virus Infection Drugs Marketby Clinics, 2018–2028(USD Billion)
27. Global Respiratory Virus Infection Drugs Marketby Drug Stores, 2018–2028(USD Billion)
28. Global Respiratory Virus Infection Drugs Marketshare, by Region, 2020 and 2028
29. North America Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
30. Europe Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
31. Asia Pacific Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
32. Latin America Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
33. The Middle East and Africa Respiratory Virus Infection Drugs Market, 2018–2028(USD Billion)
List of Tables
1. Global Respiratory Virus Infection Drugs Market: snapshot
2. Drivers of the Respiratory Virus Infection Drugs Market: impact analysis
3. North America Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
4. North America Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
5. North America Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
6. North America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
7. The U.S. Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
8. The U.S. Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
9. The U.S. Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
10. The U.S. Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
11. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
12. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
13. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
14. Rest of North America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
15. Europe Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
16. Europe Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
17. Europe Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
18. Europe Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
19. UK Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
20. UK Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
21. UK Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
22. UK Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
23. France Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
24. France Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
25. France Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
26. France Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
27. Germany Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
28. Germany Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
29. Germany Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
30. Germany Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
31. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
32. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
33. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
34. Rest of Europe Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
35. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
36. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
37. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
38. Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
39. China Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
40. China Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
41. China Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
42. China Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
43. Japan Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
44. Japan Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
45. Japan Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
46. Japan Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
47. India Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
48. India Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
49. India Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
50. India Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
51. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
52. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
53. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
54. Rest of Asia Pacific Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
55. Latin America Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
56. Latin America Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
57. Latin America Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
58. Latin America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
59. Brazil Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
60. Brazil Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
61. Brazil Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
62. Brazil Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
63. Rest of Latin America Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
64. Rest of Latin America Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
65. Rest of Latin America Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
66. Rest of Latin America Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
67. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
68. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
69. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
70. The Middle East and Africa Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
71. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
72. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
73. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
74. Saudi Arabia Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
75. South Africa Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
76. South Africa Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
77. South Africa Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
78. South Africa Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
79. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Drug Type ,2018–2028(USD Billion)
80. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Infection Type ,2018–2028(USD Billion)
81. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Route of Administration ,2018–2028(USD Billion)
82. Rest of the Middle East & Africa Respiratory Virus Infection Drugs Market revenue, By Distribution Channel ,2018–2028(USD Billion)
Request the coronavirus impact analysis across industries and markets
Massive use of artificial intelligence and machine learning in drug discovery is projected to favorably influence growth of respiratory virus infection drugs market. Humungous use of combination therapy is projected to boost rate of success of treating respiratory virus infection through anti-viral drugs. This, in turn, will facilitate elevation of respiratory virus infection drugs market size in upcoming years. Apart from this, effective drug delivery through nanotechnology is projected to provide new growth prospects for respiratory virus infection drugs market in near future. In addition to this, rise in healthcare spending & surge in vaccination activities will spur respiratory virus infection drugs industry growth. With AI-based multi-program model enabling production of antibiotic resistance drug molecules for various kinds of harmful viruses, the market for respiratory virus infection drugs is anticipated to gain traction in the years ahead. Giant pharma firms are trying to enter into partnerships with other local or regional pharma firms for developing new drugs for treating respiratory virus infections in children, thereby helping respiratory virus infection drugs market explore new areas of growth in ensuing years.
According to Zion market research report, the global Respiratory Virus Infection Drugs market accrued earnings worth approximately 40.12 (USD Billion) in 2020 and is predicted to gain revenue of about 57.23(USD Billion) by 2028, is set to record a CAGR of nearly 7.5% over the period from 2021 to 2028.
North America will contribute lucratively towards the global market value over the estimated timeline. The regional market surge is subject to new drug approvals by regulatory authorities such as U.S. FDA. Apart from this, presence of enhanced healthcare amenities along with early acceptance of advanced therapeutics in healthcare sector in countries like Canada and the U.S. will help respiratory virus infection drugs market in North America gain acceleration. Apart from this, growing healthcare awareness among the people and easy access to diagnostic tests in sub-continent will further contribute towards growth of respiratory virus infection drugs market in North America during 2021-2028.
Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No 020-46277770
US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed